BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
Retrieved on:
星期四, 十二月 7, 2023
Family, Risk, Johnson & Johnson, Aes, Infection, Q4, Physician, HCP, FDA, Thrombosis, RealTime, Venereology, JAK, BMS, Launch, Benchmarking, Patient, Safety, Psoriasis, TYK2, Malignancy, LTE, TYK, Pharmaceutical industry
There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.
Key Points:
- There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.
- One participating dermatologist highlights, “even though it's not a direct JAK inhibitor, it still is in that same family.
- Contact rates between BMS sales representatives and healthcare professionals have consistently increased, with the majority now reporting interactions with a Sotyktu representative since launch.
- An influential factor in reshaping safety perceptions regarding the oral psoriasis treatment involves BMS’ ongoing long-term-extension (LTE) trial, known as POETYK.